BEIJING KONRUNS PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.86 CNY | +1.27% |
|
+7.71% | -16.33% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,084 | 3,903 | 5,959 | 4,986 | - | - |
| Enterprise Value (EV) 1 | 5,084 | 3,903 | 5,959 | 4,986 | 4,986 | 4,986 |
| P/E ratio | 34.6 x | 38.4 x | 39.7 x | 27.5 x | 22.2 x | 17.3 x |
| Yield | - | - | 0.79% | - | - | - |
| Capitalization / Revenue | - | 4.5 x | 6.48 x | 4.63 x | 3.69 x | 3.21 x |
| EV / Revenue | - | 4.5 x | 6.48 x | 4.63 x | 3.69 x | 3.21 x |
| EV / EBITDA | - | 25.3 x | 33.1 x | 15.5 x | 14.4 x | 10.8 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | - | 1.36 x | 1.99 x | 1.59 x | 1.5 x | 1.41 x |
| Nbr of stocks (in thousands) | 1,56,491 | 1,56,491 | 1,56,491 | 1,56,491 | - | - |
| Reference price 2 | 32.49 | 24.94 | 38.08 | 31.86 | 31.86 | 31.86 |
| Announcement Date | 22/04/22 | 25/04/23 | 08/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 866.7 | 920 | 1,076 | 1,351 | 1,556 |
| EBITDA 1 | - | 154 | 179.9 | 322.5 | 345.3 | 463.5 |
| EBIT 1 | - | 140.7 | 143.3 | 245 | 302 | 390.5 |
| Operating Margin | - | 16.23% | 15.57% | 22.76% | 22.35% | 25.1% |
| Earnings before Tax (EBT) 1 | - | 140.3 | 122.7 | 239.3 | 296.3 | 386.5 |
| Net income 1 | 148 | 101.5 | 150.5 | 185.3 | 229.7 | 295 |
| Net margin | - | 11.71% | 16.35% | 17.22% | 17% | 18.96% |
| EPS 2 | 0.9400 | 0.6500 | 0.9600 | 1.160 | 1.437 | 1.845 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.3000 | - | - | - |
| Announcement Date | 22/04/22 | 25/04/23 | 08/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 3.49% | 5.03% | 5.73% | 6.73% | 8.2% |
| ROA (Net income/ Total Assets) | - | - | - | 4.4% | 5.35% | 6.3% |
| Assets 1 | - | - | - | 4,212 | 4,293 | 4,683 |
| Book Value Per Share 2 | - | 18.30 | 19.10 | 20.00 | 21.30 | 22.60 |
| Cash Flow per Share 2 | - | 0.7500 | 1.250 | 2.970 | 2.100 | 3.080 |
| Capex 1 | - | 96.3 | 101 | 7.33 | 12.3 | 58.5 |
| Capex / Sales | - | 11.11% | 10.97% | 0.68% | 0.91% | 3.76% |
| Announcement Date | 22/04/22 | 25/04/23 | 08/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
31.86
CNY
Average target price
44
CNY
Spread / Average Target
+38.10%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.33% | 682M | |
| +33.19% | 700B | |
| -4.95% | 358B | |
| +18.90% | 330B | |
| +3.77% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.20% | 161B | |
| -1.60% | 157B |
- Stock Market
- Equities
- 603590 Stock
- Financials Beijing Konruns Pharmaceutical Co.,Ltd.